Summary
Pervasive computing brings together information and communications technology (ICT) through a wide variety of computing devices. Although most medical devices are not computing devices per se, a growing number of these are coming to rely on ICT whether by means of logging and telemetry functions (e.g. portable or home healthcare devices) or through their deployment in networked hospital environments. Furthermore, with the trend towards electronic patient records, it is likely that data from all manner of medical equipment will be transmitted through healthcare ICT systems. As a result of this convergence of technologies, pervasive healthcare design engineers need to have a good understanding of the regulatory environment in which medical device development and deployment is placed, and awareness of the evidence-based and cost-sensitive processes of healthcare technology assessment. This is on top of adherence to the increasingly sector-specific engineering methods and standards that guide electrical and computing equipment product designers in order to ensure safety-critical quality devices and systems.
This chapter aims to introduce the routes and requirements for realizing medical devices, enabling the pervasive healthcare engineer to enter the minds of the regulators and assessors and to better understand the industrial processes. In the first section the concept of Health Technology Assessment is introduced, the framework that judges the effectiveness and value of a device. The second section presents the regulations pertaining to medical devices in some detail including definitions and classifications, standards and quality systems, and the key aspects of conformity processes in Europe and North America. Some newly proposed concepts in clinical trials are outlined which may, if adopted, be particularly suited to medical devices. Also covered in this section are deployment and data issues, the former to ensure continued monitoring of the device and the latter arising from the link between the predominately independent worlds of devices and computer networks that are now coming together in pervasive healthcare. The third section examines the product design process for medical devices that is being developed by the Multidisciplinary Assessment of Technology Centre for Healthcare (MATCH) research programme. The concluding section reiterates the multidisciplinary environment of the pervasive healthcare innovator, and points to sources of information and advice.
Health technology assessment

The evidence-based environment
Design engineers should already be intimately familiar with the concepts of product lifecycle, quality control standards and regulations, and increasingly with the need to take a user-centered approach. For successful healthcare technology development, however, we must include two additional concepts: firstly evidence-based practice, which began in clinical medicine but is now commonplace across healthcare including areas such as information management and device or facility design, and secondly an understanding of reimbursement processes for healthcare technologies. For the purposes of this chapter these two concepts are tied together into the process known as Health Technology Assessment (HTA).
Evidence-based practice is described by Booth The entrance of evidence-based practice in the context of healthcare technologies means not only that a new design should show efficacy in relation to risk for a specific therapeutic procedure by the gathering of appropriate clinical evidence (which may be mandatory, depending on the device class), but that it must prove its clinical effectiveness with respect to existing alternatives in terms of both efficacy and cost, and according to the healthcare allocation policy of the payer (e.g. equitable provision, or otherwise, of a treatment). Therefore evidence-based practice as related to healthcare technologies can be regarded to a great extent as the antithesis of the technology-push mentality found in the marketing of consumer electronics.
The implication for design engineers is that knowledge of its future assessment should feed into the development process of a device or system at as early a stage as possible, so that the appropriate design choices are made. As Baxter shows, early investment in the front-end of the design process is an important general principle for producing any successful new product, such that 85%-90% of its overall costs will have already been committed by decisions made before detailed design or production engineering begins. 2 This figure may be even greater for medical devices because modifying a design at a late stage means retracing expensive and time-consuming regulatory processes.
Reimbursement issues
Most medical technology products are quite different from consumer products since very few are available over-the-counter, and patients do not often pay the full cost of a device-related medical procedure or diagnostic test themselves. Instead, a medical device manufacturer will seek reimbursement from the patient's healthcare provider, who may be a public institution like a national health service or a private body such as a private clinic or health insurer. Reimbursement mechanisms vary greatly between different countries (and even between regions within some countries) and are quite complex in terms of the different mixes of public and private systems and product types covered. Access to specific healthcare products, especially in private care regimes, may also depend on patient factors such as age, income and employment status. From the technology manufacturer's point of view, this presents an unhelpfully fragmented and non-harmonized environment to market their products in.
As highlighted in a comprehensive Clinica report on reimbursement by Bromley et al., devices are being heavily implicated as a major cost driver for healthcare, and clinical evidence is increasingly being called for by the payers to justify these costs, whether it is for large capital items used for diagnostics or personal devices. 3 Papatheofanis outlines five economic variables that payers typically use for health economic analysis: cost of therapy, cost of side-effects, costs avoided as a result of treatment, costs utilized based on information from diagnostics or referral of a patient, and costs utilized or saved during extended years of life as a result of therapy. 4 For the design engineer, this necessitates some understanding of both treatment and funding pathways that a device will be involved in, and of the decision-making processes involved in having a device accepted for reimbursement. Detailed coverage of reimbursement methods is beyond the scope of this chapter, but it is worth mentioning the growth in popularity of a formal method known as Diagnostic Related Groups (DRGs) that was introduced by the major US health insurer Medicare and now has variants in many countries of the EU, Japan and Australia. DRGs are a classification of hospital case types into groups expected to have similar hospital resource use, which code for a tariff that is calculated from a fixed base rate along with a weighting to adjust for hospital size and other factors. An important characteristic of the DRG method of reimbursement is that it is not based on the cost of a device alone, but rather by the entire cost of the hospital resources made up by the clinical interventions and services required for diagnosis and treatment of a disease, plus its possible complications or comorbidities. Tariffs are intended to be updated on a regular basis (at least every few years) so that they represent the true cost of the procedure. DRGs introduce a high degree of transparency into the reimbursement process, but their existence makes it all the more important to predict how a device will map to all of its intended uses with their various reimbursement codes and to use this knowledge to inform early decision-making.
Health Technology and the role of HTA bodies
Health Technology Assessment (HTA) aims to provide information to support healthcare decisions and policy making at local, national and international levels. 
Medical devices and their regulation 2.1 Definitions, principles and classes
Medical devices are highly regulated. This is essential to ensure patient and practitioner safety, good performance and quality of manufacture in the pre-market stage, correct listing and advertising of the device that is being placed on the market, and fulfillment of post-market obligations such as detecting and alerting users of any problems and monitoring of a device's clinical performance. The following sections are intended to give the reader an introduction to the essential pre-market regulatory processes and some of the post-market obligations with respect to the planning and realization of a device.
Definitions
The first step in the regulatory process towards marketing a medical technology product is knowing that it is a medical device. Definitions and nomenclatures for medical devices are not internationally agreed although this is being worked on by the Global Harmonization Task Force (GHTF), which was founded in the 1992 by the European Union (EU), United States (US), Canada, Australia and Japan. 8 These efforts have been facilitated by the passing of EU-wide harmonization legislation, the US Federal Drug Administration (FDA) Modernization Act, and through substantial adoption of GHTF recommended models by the Therapeutic Goods Administration (TGA) in Australia, the Therapeutic Products Directorate (TPD) in Canada, and by Japan's Ministry of Health, Labor, and Welfare (MHLW). Naming of devices is becoming standardized via ISO 15225 Nomenclature -Specification for a nomenclature system for medical devices for the purposes of regulatory data exchange, which is helping to facilitate international consensus on a Global Medical Device Nomenclature (GMDN) that is endorsed by the GHTF. The GHTF has proposed a harmonized definition for medical devices (document SG1/N029R11), 8 but it is instructive to see the differences between the US and EU as they currently stand. Therefore, definitions for medical devices in the two regions will now be considered. Part of the rationale behind the form of these definitions is to distinguish devices from pharmaceutical products. Although from a patient's point of view, devices and drugs are complementary parts of managing their health, there are some important differences from HTA 7 and other perspectives as shown in Table 1 . Within MDD definitions an infusion pump that supplies a pharmaceutical is a device whereas a conventional pill capsule is not, and some drug-device combinations are also covered as devices. It is worth noting that some recent developments such as biologic coatings, tissue-engineered products and other drug-device combinations are further pushing at the borderline, so that clarifications to legislation have been and continue to be necessary. (INSERT TABLE 1 ABOUT HERE -find table after references)
Essential principles
In addition to definitions, the MDD provides Minimum Essential Requirements (Annex I) for the design and manufacture of medical devices to ensure the protection of the health and safety of patients, users and third parties, which makes safety a central principle in the legislation 11 . The requirements include (although this list is not exhaustive):
 a general requirement for inherently safe design and construction,  safety and compatibility of materials, including medicines if acting as an ancillary device,  no adverse effect on characteristics or performance from normal use, transportation or storage,  elimination, minimization, protection against and informing of risk, ensuring residual risk is acceptable when weighed against benefit to the patient. 
Device Classes
Once you know your product is a medical device, the next important step is to know its class since this determines the route to conformity. Again, although not universally agreed by regulators, there is a degree of harmonization whereby medical devices are classified into three or four classes according to level of risk, use and degree of invasiveness. The higher the risk, the higher the class number. Devices may also be classified during development e.g. the FDA classifies investigational devices in two classes: Significant Risk (SR) or Non-Significant Risk (NSR).
Currently, however, there are alternative approaches to actually determining the device class for a new device. In the EU this is done by applying a set of 18 rules (as specified in MDD Annex IX) with additional special rules for Active Implantable Medical devices and In Vitro Diagnostic devices, whereas in the US classification is carried out by government expert panels under Title 21 of the Code of Federal Regulations (CFR) whereby a device is generally assumed to be high risk unless it can be shown otherwise. The panel method can introduce uncertainty into the process, which can be especially worrying if the device is bordering on high risk since this increases the cost of obtaining conformity. On the other hand, a rulebased type method can be difficult to apply although for the MDD there are some useful additional guideline documents. 12 Table 2 shows the types of devices in the various classes which result from the MDD rules. Non-active and accessory equipment is classified along with the active devices that are of most interest to pervasive healthcare designers. Further discussion about classification in the EU and US and global trends can be found in Davey et al.
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( INSERT TABLE 2 ABOUT HERE -find table after references)
Regulatory matters 2.2.1 Conformity
Conformity is the successful outcome of the compulsory regulatory processes by which a medical device will be accepted for marketing in a particular region. In the EU, conformity is shown by obtaining CE marking which means the device is certified to have met regulatory requirements. This includes adherence to the essential principles of the directives as assessed by an accredited third party (Notified Body) in the case of Class II/III devices or via self-assessment in the case of a Class I low risk device (provided the company is registered as meeting a quality systems management standard). In the UK, notified bodies are audited by the Medicines and Healthcare products Regulatory Agency (MHRA) of the Department of Health. In the US, conformity is shown by obtaining FDA approval from the government by going through one of two processes. Premarket approval (PMA) involves demonstration of reasonable safety and effectiveness which is required for a high-risk or new kind of device. A less-stringent Premarket Notification 510(k) process is allowed for devices that are substantially equivalent (SE) to a device already on the market, known as a predicate device. Some 1,700 devices are already classified by the FDA so it is essential for the innovator of a device to check for substantial equivalence in determining the likely route to compliance for marketing it in the US. An illustrative example of SE devices are 3D navigation systems for computer-aided orthopedic surgery which are predicated to stereotaxic equipment that was originally developed for neurosurgery. Because of this several manufacturers have obtained approval via the 510(k) route. In contrast, companies found it difficult to obtain FDA approval for robotic orthopedic surgery systems due in part to the lack of a suitable predicate device, which therefore necessitated the PMA route.
Standards
Adherence to product standards is a vital component of the regulatory process, and although pre-market standards vary in format in different regions, they universally apply to three main areas according to the World Health Organization: There is also a fairly recent comprehensive reference by Fries. 16 Device attributes standards are very much related to the essence of the essential requirements as previously described for the MDD. Data standards, since they are very important to pervasive systems, will be considered later on in this section. Standards for clinical studies, although linked to safety and performance, will also be mentioned in a separate section. Manufacturing standards are for the most part covered by quality assurance (QA) systems that are required for the production and testing of all classes of device. In the EU this is now covered by the medical device standard ISO 13845. In the US, a company must follow Good Manufacturing Practice/Quality Systems (GMP/QS) standards. These standards require design controls and documentation for the manufacturing process. Labeling standards contribute to safe use and tracking of products.
Rather than go into specific details, it is perhaps more useful in a changing regulatory environment to examine trends in the evolution of standards in recent years, as follows (with relevant examples):
 Regulations are subsuming many voluntary standards, which is deemed useful because it is easier to change a standard than a regulation and this also aids governments in creating regulations. An exception is the area of environment protection which is becoming more regulated (see below).  Usability engineering is becoming less of a guideline and more of a requirement. This is related to risk management and arose from the need to understand and mitigate potential misuse. In particular usability will be fully incorporated into the 3rd edition of IEC 60101 and the scope of use will also change from 'under medical supervision' to 'all use'. This is alongside recognition of the need to have tight controls on home use.
 Sustainability and environmental protection are becoming more regulated, building on voluntary environmental management standards such as ISO 14001. Example include the EU's Waste from Electrical & Electronic Equipment (WEEE) and Restriction of Certain Hazardous Substances (RoHS) directives and Integrated Product Policy (IPP)
, where greater responsibility is placed on manufacturers regarding the disposal of devices, necessitating 'cradle-to-grave' engineering. The Eco-design requirements for energy-using products (EuP) directive is intended to make electrical devices more environmentally friendly. Japan has also passed a set of
environmental laws including Home Appliances Recycling Law (HARL), Law for the Effective Utilization of Resources (LPEUR) and Green Purchasing Law (GPL).
 Recognition is rising regarding the need to ensure safety of refurbished and denoted equipment as well as the reprocessing of devices labeled for single-use. This includes equipment intended for reuse in developed countries, and, for trade and donation of equipment to developing countries, some of whom have previously had bad experiences with used equipment. 
Post-market surveillance, vigilance and adverse incident reporting
Once a device is on the market and is being used by practitioners and patients, it is important that its safety and performance continue to be assessed. Devices can be used and misused in many different and unforeseen ways (perhaps as a result of inadequate labeling and user instructions) and, in spite of premarket efforts, can fail in actual use or otherwise incur complaints from customers. Changes in clinical practice may also impact on actual use of a device, while advances in state-of-the-art technology can demand changes to a design. This is quite apart from the processes of HTA which as we have seen are used to assess and reassess clinical effectiveness and cost effectiveness for policy-making purposes.
The two main methods by which post-market assessment is implemented are post-market surveillance (PMS) studies by the manufacturer and by gathering and disseminating information through adverseincident reporting networks. In Europe a related term vigilance is used to denote the responsibility of the manufacturer to track and report on problems arising with a device. 
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Data security is an issue that is receiving particular attention with the introduction of electronic patient records. In the US, the Health Insurance Portability and Accountability Act (HIPAA) requires, as of 21 April 2005 , that healthcare providers adopt a security procedure to ensure the integrity, availability and confidentiality of information maintained and transmitted by medical devices. 20 From a service provision perspective, Grimes outlines the need to shift from management of discrete devices towards an overall policy of safeguarding information, and lists a range of device and system requirements that might be used to mitigate security threats. 21 These threats include hardware failures or errors, user misuse or abuse of a device, erroneous data entry, malicious assault, unauthorized data access and/or modification, and environmental effects such as electromagnetic interference (EMI) or interruption of utilities such as power. These and other issues related to data handling and protection must therefore feed into the design process for pervasive healthcare devices and systems.
Clinical studies
A key aspect within the pre-market processes for proving and approving medical devices is the gathering and use of data concerning its clinical efficacy and safety. For certain classes of device, clinical approval resulting from the outcomes of testing on human subjects will be mandatory for its market certification. This might involve actual clinical studies or the compilation and critical analysis of existing evidence from the literature and other sources concerning similar devices. 22 Even for low risk devices, clinical data may be important for proving the need and benefits of a product to users and payers.
Pre-market clinical studies typically take place after detailed design of the device is completed. Data which is intended to be used for predicting clinical effectiveness on living humans, especially for invasive devices, is also commonly obtained in the development stage from animal experiments, human cadavers and tissue. Pre-clinical information may also be gained from systematic consultation of individuals or groups of healthcare professionals and patients, as well as from modeling exercises.
If the conducting of a clinical trial is necessary due to insufficient existing evidence, the manufacturer is required to follow procedures in applying for permission to do so, and for the running of the trial. The processes for doing this are regulated by the same bodies as in section 2. Devices for Human Subjects covers recognized practices for conducting trials. In the US, and elsewhere, clinical and laboratory practices are governed by requirements known as Good Clinical Practices (GCP) and Good Laboratory Practices (GLP).
many countries as a result of greater attention to animal welfare issues, the question of efficacy of animal models and cost, and especially due to a more concerted adoption of the principles of the 3R'sreplacement, reduction and refinement of animal use. In Australia, this has become most sophisticated by means of the Animal Ethics Committees (AECs) that have been introduced into animal welfare legislation through a revised Australian code of practice for the care and use of animals for scientific purposes. 26 The
AECs act as decision-making bodies a similar manner to RECs. In the UK, a government-funded Centre for the 3R's has recently been established whose stated aim is the ultimate replacement of animal use. 27 Further information about research ethics for both humans and animals can be obtained via the Online Ethics Center website. 28 In addition to RECs there are a number of other types of ethics committees. In the UK for example, Clinical Ethics Committees (CECs) provide advice and support on ethical issues arising from clinical practice and patient care within health care organizations. 29 Although these committees are not decision-making bodies like RECs, they may influence aspects of healthcare such as hospital procedures and equity of access, which may be quite relevant to a technology developer. Finally, ethics in business is experiencing a growth in concern within the medical device sector, which is relevant to the collaboration of companies with healthcare professionals (HCPs 
Advances in clinical trials for devices
The 'gold standard' for clinical trials is the Randomized Controlled Trial (RCT) that was developed for evaluating drug treatments but is now used for the full range of clinical procedures. However, there are some problems associated with RCTs for medical devices because of the differences between devices and drugs as shown previously in Table 1 . In a useful illustration of this, Lilford et al. have outlined some of the issues involved in surgical trials, which often involve devices, showing how application of the RCT can be problematic. 31 These issues include ethics of intervention versus non-intervention, the problem of blinding of participants (surgeons, patients and hospital staff), surgeon-and technique-related variables, timing of trials, patient preferences, entry criteria, appropriate outcome measures, and a number of statistical considerations. As a result, less powerful clinical studies, such as cohort studies and casestudies, are quite prevalent in the literature for medical devices. However, the value of studies lower down in the hierarchy of evidence can be difficult to assess from the HTA perspective. Lilford et al. argue strongly for randomization and in a separate paper propose tracker trials for comparing fast-changing technologies like devices. 32 Tracker trials include the set of contemporary examples of treatments employed by clinicians but allow for the addition of new devices and treatments into the study as the trial progresses. This is to help ensure early adoption if a new procedure is found to be superior, as well as for removal of a procedure if it shown to be performing poorly or if it has been superseded by technological developments. These are still randomized trials, but they do not have preset and rigid protocols and are ongoing studies rather than the one-off event that characterizes an RCT. New developments of this kind may become influential in the future of medical device assessments.
Routes for medical devices innovation
Having covered some of the nuts and bolts of medical device development and their accompanying regulations and standards in the previous two sections, we are now in a position to look at the overall innovation process.
New product development processes
New Product Development (NPD) methods typically break the innovation process down into a series of stages with associated decision-making, called stage-gate systems. 33 Such processes are aimed at helping to reduce development time and improving quality through standardization of practice and subsequent capture of best practice. Rochford and Rudelius have studied medical devices in this context, comparing 'new-to-the-world' products and product modifications using a 12-stage process. 34 Members of the author's Multidisciplinary Assessment of Technology Centre for Healthcare (MATCH) have recently completed a consultation with our industrial partners that has resulted in a simplified 4-stage generic process for medical devices, giving a snap-shot of the current approach to product development in the industry 35, 36 . This process is summarized in Figure 1 . Much of the progression of stages will be familiar to project managers and product developers. However, there are some points for special note. Firstly, there will be more stages in practice. The 4-stage model is intended to be a high-level representation of the decision-making steps involved. Secondly, as a result of the regulatory processes that must be undertaken, the first three stages involve a great deal of planning before detailed product design can be attempted, after which strict design controls must be in place to track and document all modifications. This is quite typical of safety-critical systems. These controls and the validation processes that close the iterative loops during Stage 3 have received attention by others in terms of guidance to the medical device industry (e.g. the Cambridge Engineering Design Centre's Design for Validation approach). 37 (INSERT FIGURE 1 ABOUT HERE -find figure after references) A notable omission in documented current practice is specific planning for HTA and reimbursement as mentioned earlier in the chapter. This is being addressed in MATCH by the promotion of health economics modeling 38 which would benefit from its earliest adoption in Stage 1, with subsequent refinement at other stages, such as during clinical trials. 39 The other main omissions are the environmental and sustainability strategies that will have to be put in place as the newer regulations are introduced. These will require the industry to go beyond dealing with retirement of obsolete devices and towards advance planning for disposal at the point when detailed requirements are drawn up and design decisions involving choices of materials and energy use are made. Sourcing, procurement, reporting, servicing and repair are all areas that will be affected by such legislation. 40 A further development areas is the approach to stakeholder requirements, especially in the area of user needs capture to ensure devices are fit-for-purpose. As we have seen this is another area that is moving from guidance towards regulation, and will benefit from review throughout the lifecycle, suggesting the introduction of more formal human factors methods into the concept design phase of Stage 2 and specific planning for usability testing in Stage 3.
Special considerations for pervasive medical device development
For devices involving data, which are inherent to pervasive computing in healthcare, the communication and security issues mentioned earlier will need specific planning for since they will impact on design choices, user testing and post-market surveillance. Since regulations and standards are in continual development it will be most beneficial for pervasive healthcare designers to engage with the bodies concerned with these. Interaction with patient groups will help provide insights into public concerns about protection of personal records.
Since many pervasive healthcare devices are likely to be used in the home, this raises obvious concerns in the area of maintenance and disposal/recycling as mentioned above. Comparison with the experiences of deploying equipment for disabled users by healthcare providers would be useful in this respect. As well as those supplied by professionals, many pervasive healthcare devices are likely to be purchased over-thecounter, and this will raise further issues such as ensuring adequate training.
Finally, the best combined methods to use for user needs capture of pervasive healthcare devices in conjunction with the ICT systems they interact with is still an open question that would benefit from further research.
Conclusions
The environment of the pervasive healthcare innovator is a multidisciplinary one, bringing together the roles of the clinical designer/engineer and ICT specialist. It is hoped that this chapter has provided an insight into the processes of healthcare technology development. On the device side especially, there is a need for understanding the regulatory processes within the product life-cycle plus other aspects which might normally be outside a designers remit, such as reimbursement and HTA processes. Bringing this knowledge into the design process should help to improve decision-making in medical device innovation.
In a large medical devices organization, there will most likely be expert individuals and departments in some of the specific areas outlined in this chapter such as clinical trials and regulations so it will not be necessary for designers to have detailed knowledge of these. Of course, this is the benefit of a multidisciplinary team. For a small company or university research group, however, it is more likely that individuals will need to become multidisciplinary to some extent.
Medical device regulations and standards are presently going through great changes and the web has become an important medium for accessing the latest information and advice, highlighted by the large number of online references in this chapter. , are further useful sources of advice and information for medical technology developers.
Pervasive computing is an exciting field that should contribute in addressing and solving many of issues involved in developing new healthcare technologies and bringing them to patients. 
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